Rigaku: Novel Electron Density Topography Technology to Reveal Biological Macromolecules’ Properties
Rigaku Corporation, a Rigaku Holdings Group company and global partner for X-ray analysis from Lab to Fab (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; "Rigaku"), has developed a technology called Electron Density Topography (“EDT”), patents pending. The new technology clarifies the structure and dynamic characteristics of biological macromolecules, including antibodies, protein complexes, and virus particles, in solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903386305/en/
EDT device (Photo: Business Wire)
EDT enables direct observation of biological macromolecules in solution, reducing artifacts resulting from measurement conditions. EDT is anticipated to improve the R&D processes for innovative biopharmaceuticals, including monoclonal antibody-based therapies and advanced drug delivery systems.
EDT provides information about the overall shape, molecular characteristics and internal structure of biological macromolecules from the distribution of electrons that determines a molecule's chemical properties. EDT has also enabled direct observation of the electron density of biological macromolecules without prior information about the samples.
In drug discovery, there is a clear need to determine at the early stages of development whether a drug has the expected structure and desired characteristics to optimize resources. EDT is a technology that meets this requirement and is expected to be used in basic research and development for biopharmaceuticals such as antibody drugs.
The first instrument with EDT capabilities will be deployed at Rigaku's Life Science Laboratory, a facility in Cambridge, Massachusetts, in Q4 2024.
Rigaku is committed to expanding its operations in the life sciences field, strengthening its presence to drive further innovation in collaboration with customers.
About The Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including in its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku-holdings.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903386305/en/
Contacts
Sawa Himeno
Head of Communications Dept., Rigaku Holdings Corporation
+81 90 6331 9843
prad@rigaku.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair12.9.2024 01:05:00 EEST | Press release
Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair. This designation follows the results from the Phase 2 NEUROFUSE study and several interactions with the FDA. NTX-001 has the potential to be a groundbreaking therapy in the field of nerve repair. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240911372663/en/ Evan L. Tzanis, Chief Operating Officer and EVP of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire) Neuraptive is preparing to launch a Phase 3 pivotal program for NTX-001 in early 2025. The program will consist of a single randomized, double-blind, placebo-controlled study assessing the efficacy and safety of NTX-001 in patients with peripheral nerve injury requiring repair. The final protocol for this single Phase 3 study is currently b
Mouser Electronics Explores Sustainable Smart Grid Innovation in Latest Content Series11.9.2024 18:41:00 EEST | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today released the latest installment of its Empowering Innovation Together (EIT) technology series, which explores the benefits of incorporating renewable energy into smart grid technology, emphasizing the role of AI and 5G in achieving sustainable grid management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240911011855/en/ In the latest installment of its Empowering Innovation Together (EIT) technology series, Mouser explores the benefits of incorporating renewable energy into smart grid technology, emphasizing the role of AI and 5G in achieving sustainable grid management. (Photo: Business Wire) Adopting a smart grid system enhances the precision of power usage monitoring and energy distribution and enables two-way communication between the system and users. This decentralized approach
Delinea Named a Leader in 2024 Gartner ® Magic Quadrant™ for Privileged Access Management11.9.2024 18:30:00 EEST | Press release
Delinea, a pioneering provider of solutions for securing identities through centralized authorization, today announced its recognition as a Leader in the 2024 Gartner Magic Quadrant for Privileged Access Management (PAM). This marks the 6th consecutive time that Delinea has been acknowledged in the Leaders Quadrant; Delinea stated that, in their opinion, this highlights the company's ongoing commitment to delivering market-trusted security solutions. “We are honored to be recognized once again as a Leader by Gartner,” said Art Gilliland, CEO of Delinea. “Identity security serves as the first line of defense, as every identity, both human and non-human, and the data with which they interact are targets in today’s modern enterprises. I believe this acknowledgement reaffirms our commitment to safeguarding our clients while delivering solutions that not only enhance security but also remove complexity, elevating the user experience.” As Gartner states, “growth continues to be driven by the
CyberArk Named a Leader in the 2024 Gartner® Magic Quadrant™ for Privileged Access Management11.9.2024 18:04:00 EEST | Press release
CyberArk (NASDAQ: CYBR), the identity security company, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Privileged Access Management.1 CyberArk is positioned as a Leader for the sixth consecutive time and is positioned furthest in Completeness of Vision, which evaluates vendors on offering (product) strategy, innovation and market understanding among other evaluation criteria. With 93% of organizations suffering two or more identity-related breaches in the last 12 months, managing and securing identities has become a critical requirement. The CyberArk Identity Security Platform enables organizations to secure the entire spectrum of identities, including workforce, IT, developer and machine, supporting modern access use cases such as the need to enforce Zero Standing Privileges in public cloud environments. A core component of the platform is CyberArk’s privileged access management (PAM) capabilities, which allow customers to apply flexible privilege
Spencer Health Solutions Achieves ISO 27001 Certification11.9.2024 16:55:00 EEST | Press release
Spencer Health Solutions (SHS), a healthcare technology leader in smart medication management, announced that it has achieved ISO 27001:2022 certification. This prestigious accreditation underscores the company's unwavering commitment to safeguarding patient data and ensuring the highest standards of information security. ISO 27001 is a globally recognized information security management system (ISMS) standard that ensures organizations implement robust measures to protect their assets from threats. By achieving this certification, Spencer Health Solutions has demonstrated its dedication to: Confidentiality: Protecting patient data from unauthorized disclosure. Integrity: Ensuring the accuracy and completeness of medication dispensing records. Availability: Guaranteeing timely access to medication dispensing information when needed. “We are proud to announce that Spencer Health Solutions has achieved ISO 27001 certification,” said Tom Rhoads, CEO of Spencer Health Solutions. “This acco
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom